---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-26-000081"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2026-06-18T12:01:46+00:00"
generated_at: "2026-06-18T12:05:17.590832+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Denali sells Rare Pediatric Disease PRV for $195M to fund pipeline

## Summary
- Gross proceeds of $195M from sale of PRV awarded after FDA approval of AVLAYAH for Hunter syndrome in March 2026.
- Proceeds to advance clinical pipeline including DNL126 (MPS IIIA), DNL593 (FTD), DNL952 (Pompe), DNL628 (Alzheimer's).
- Transaction subject to HSR waiting period; expected to close after customary conditions.
- Denali's TV platform enabled AVLAYAH, first FDA-approved biologic to cross blood-brain barrier via transferrin receptor.

## SEC filing metadata
- accession: 0001714899-26-000081
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2026-06-18T12:01:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/0001714899-26-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/dnli-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-26-000081
- JSON: https://secwatch.observer/filing/0001714899-26-000081.json
- Plain text: https://secwatch.observer/filing/0001714899-26-000081.txt

## Key facts
- Material Agreements
  Denali Therapeutics Inc. entered into PRV Transfer Agreement valued at $195 million (effective 2026-06-12).
  - Action: entry
  - Agreement: asset purchase
  - Value: $195 million
  - Effective: 2026-06-12
  source text: On June 12, 2026, Denali Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/0001714899-26-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.